1
|
Al-Ani A, Szell PMJ, Rehman Z, Blade H, Wheatcroft HP, Hughes LP, Brown SP, Wilson CC. Combining X-ray and NMR Crystallography to Explore the Crystallographic Disorder in Salbutamol Oxalate. CRYSTAL GROWTH & DESIGN 2022; 22:4696-4707. [PMID: 35971412 PMCID: PMC9374327 DOI: 10.1021/acs.cgd.1c01093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 06/30/2022] [Indexed: 06/15/2023]
Abstract
Salbutamol is an active pharmaceutical ingredient commonly used to treat respiratory distress and is listed by the World Health Organization as an essential medicine. Here, we establish the crystal structure of its oxalate form, salbutamol oxalate, and explore the nature of its crystallographic disorder by combined X-ray crystallography and 13C cross-polarization (CP) magic-angle spinning (MAS) solid-state NMR. The *C-OH chiral center of salbutamol (note that the crystal structures are a racemic mixture of the two enantiomers of salbutamol) is disordered over two positions, and the tert-butyl group is rotating rapidly, as revealed by 13C solid-state NMR. The impact of crystallization conditions on the disorder was investigated, finding variations in the occupancy ratio of the *C-OH chiral center between single crystals and a consistency across samples in the bulk powder. Overall, this work highlights the contrast between investigating crystallographic disorder by X-ray diffraction and solid-state NMR experiment, and gauge-including projector-augmented-wave (GIPAW) density functional theory (DFT) calculations, with their combined use, yielding an improved understanding of the nature of the crystallographic disorder between the local (i.e., as viewed by NMR) and longer-range periodic (i.e., as viewed by diffraction) scale.
Collapse
Affiliation(s)
- Aneesa
J. Al-Ani
- Centre
for Sustainable and Circular Technologies (CSCT), University of Bath, Claverton Down, Bath BA2
7AY, U.K.
| | | | - Zainab Rehman
- Department
of Physics, University of Warwick, Coventry CV4 7AL, U.K.
| | - Helen Blade
- Oral
Product Development, Pharmaceutical Technology & Development,
Operations, AstraZeneca, Macclesfield SK10 2NA, U.K.
| | - Helen P. Wheatcroft
- Chemical
Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K.
| | - Leslie P. Hughes
- Oral
Product Development, Pharmaceutical Technology & Development,
Operations, AstraZeneca, Macclesfield SK10 2NA, U.K.
| | - Steven P. Brown
- Department
of Physics, University of Warwick, Coventry CV4 7AL, U.K.
| | - Chick C. Wilson
- Centre
for Sustainable and Circular Technologies (CSCT), University of Bath, Claverton Down, Bath BA2
7AY, U.K.
| |
Collapse
|
2
|
Bradley JP, Pickard CJ, Burley JC, Martin DR, Hughes LP, Cosgrove SD, Brown SP. Probing Intermolecular Hydrogen Bonding in Sibenadet Hydrochloride Polymorphs by High-Resolution 1H Double-Quantum Solid-State NMR Spectroscopy. J Pharm Sci 2012; 101:1821-30. [DOI: 10.1002/jps.23078] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2011] [Revised: 01/09/2012] [Accepted: 01/20/2012] [Indexed: 01/18/2023]
|
3
|
Clawson JS, Kennedy-Gabb S, Lee AY, Copley RCB. One-phase crystal disorder in pharmaceutical solids and its implication for solid-state stability. J Pharm Sci 2011; 100:4302-16. [PMID: 21590691 DOI: 10.1002/jps.22621] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2010] [Revised: 03/08/2011] [Accepted: 04/21/2011] [Indexed: 01/13/2023]
Abstract
Solid-state disorders of active pharmaceutical ingredients have been characterized by means of X-ray diffraction techniques and solid-state nuclear magnetic resonance spectroscopy. The results determined that the pleuromutilin-derivative, I, displays a unique continuous conformational disorder while retaining its long-range crystalline structure. The propionic acid (PA) version of this compound displayed partial crystalline order and site disorder of PA, depending on the quantity of PA incorporated in the structure. Thus, I is a unique example of one-phase crystalline-amorphous model. Physical and chemical stability data was acquired on these disordered systems and discussed in relation with the characterized disorder present in the crystal systems. Analysis of the results showed that in contrast to phase-separated amorphous, restrained disorders do not influence the stability.
Collapse
Affiliation(s)
- Jacalyn S Clawson
- Product Development, GlaxoSmithKline plc., King of Prussia, Pennsylvania 19406.
| | | | | | | |
Collapse
|
4
|
Albers D, Galgoci M, King D, Miller D, Newman R, Peerey L, Tai E, Wolf R. Characterization of the Polymorphic Behavior of an Organic Compound Using a Dynamic Thermal and X-ray Powder Diffraction Technique. Org Process Res Dev 2007. [DOI: 10.1021/op700037w] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- David Albers
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Michelle Galgoci
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Dan King
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Daniel Miller
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Robert Newman
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Linda Peerey
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Eva Tai
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| | - Richard Wolf
- Dowpharma Department, The Dow Chemical Company, 1710 Building, and Department of Analytical Sciences, The Dow Chemical Company, 1897 Building, Midland, Michigan 48674, U.S.A
| |
Collapse
|
5
|
Abstract
Papers and patents that deal with polymorphism (crystal systems for which a substance can exist in structures characterized by different unit cells, but where each of the forms consists of exactly the same elemental composition) and solvatomorphism (systems where the crystal structures of the substance are defined by different unit cells, but where these unit cells differ in their elemental composition through the inclusion of one or molecules of solvent) have been summarized in an annual review. The works cited in this review were published during 2005, and were drawn primarily from the major physical, crystallographic, and pharmaceutical journals. The review is divided into sections that cover articles of general interest, computational and theoretical studies, preparative and isolation methods, structural characterization and properties of polymorphic and solvatomorphic systems, studies of phase transformations, effects associated with secondary processing, and United States patents issued during 2005.
Collapse
Affiliation(s)
- Harry G Brittain
- Center for Pharmaceutical Physics, 10 Charles Road, Milford, New Jersey 08848, USA
| |
Collapse
|